Association between FOXP3+ regulatory T-cells and occurrence of peritoneal lesions in women with ovarian endometrioma and dermoid cyst
Publication date: Available online 31 January 2019Source: Reproductive BioMedicine OnlineAuthor(s): Khaleque N Khan, Kazuo Yamamoto, Akira Fujishita, Akemi Koshiba, Haruo Kuroboshi, Satomi Sakabayashi, Satoshi Teramukai, Masahiro Nakashima, Jo KitawakiAbstractResearch questionIs there any relationship between the numbers of FOXP3+ regulatory T-cells (Treg) and occurrence of peritoneal lesions in women with ovarian endometrioma and dermoid cyst?DesignThis is a retrospective cohort study and prospective case-controlled biological research. Peritoneal lesions and peritoneal fluid (PF) were collected from 27 women with ovarian endometrioma (chocolate cysts) and 25 women with dermoid cyst. Tissue expression of Forkhead box P3 (FOXP3), one of the transcription factors of Treg cells, and transforming growth factor-beta (TGF-β) were examined by immunohistochemistry. Interleukin-6 (IL-6) and TGF-β levels in the PF was measured by ELISA.ResultsComparing to 269/350 (76.9%) cases with ovarian endometrioma with coexisting peritoneal lesions, 74/414 (17.8%) cases with dermoid cyst had coexistent peritoneal lesions and this difference was statistically significant (P
Publication date: Available online 2 June 2020Source: European Journal of Obstetrics &Gynecology and Reproductive BiologyAuthor(s): Sabine Moehner, Kerstin Becker, Jens A. Lange, Sophia von Stockum, Klaas Heinemann
SPONSORED POST By BAYER G4A Digital health is changing the world From chronic disease management to prevention, G4A’s goal is to empower people with the tools and access they need to take control of their health. G4A does this through fostering a diverse and vibrant ecosystem of digital health partners to support their growth and impact. On April 20th, G4A launched its 2020 Partnership Program with an open call for applications. The aim of the Partnerships Program is to work with companies across the globe on healthcare’s toughest challenges and innovate together towards a future of integrated ...
Dienogest (DNG) 2 mg (Visanne) was approved for endometriosis treatment in Europe in 2010. The Visanne Post-approval Observational Study (VIPOS) was designed to assess the safety of DNG 2 mg/day compared to other hormonal endometriosis treatments, focusing especially on clinically relevant depression and anemia.
ConclusionsAlthough no human studies have been performed so far, the cell and animal model study results suggest that LXA4 will be used in obstetrics and gynecology soon.
Condition: Endometriosis, Rectum Interventions: Diagnostic Test: Transvaginal ultrasound; Behavioral: 5-point Likert scale Sponsor: Ospedale Policlinico San Martino Completed
Publication date: Available online 14 May 2020Source: Reproductive BioMedicine OnlineAuthor(s): Jessica Ottolina, Matteo Schimberni, Sofia Makieva, Ludovica Bartiromo, Teresa Fazia, Luisa Bernardinelli, Paola Viganò, Massimo Candiani, Davide Gentilini
Publication date: Available online 21 May 2020Source: European Journal of Obstetrics &Gynecology and Reproductive BiologyAuthor(s): Tomasz Szaflik, Beata Smolarz, Hanna Romanowicz, Magdalena Bryś, Ewa Forma, Krzysztof Szyłło
Publication date: Available online 31 May 2020Source: PhytomedicineAuthor(s): Yi-Wen Hsu, Hsin-Yuan Chen, Yi-Fen Chiang, Li-Chun Chang, Po-Han Lin, Shih-Min Hsia
To evaluate the rate of postoperative complications between conservative surgery and segmental resection in patients with rectal endometriosis.
To identify novel candidate diagnostic microRNA (miRNA) markers of endometriosis by means of an unbiased search with confirmation by means of targeted polymerase chain reaction (PCR).